Showing 10 posts of 10 posts found.


Minerva’s insomnia treatment beats Ambien in Phase 2b trial

June 25, 2019
Manufacturing and Production MDD, Minerva Neurosciences, Placebo, ambien, insomnia, pharma, zolpidem

Massachusetts-based firm Minerva Neurosciences has announced that its sleeping pill seltorexant beat both Sanofi’s Ambien (zolpidem) and placebo in treating …


Ambien and other insomnia meds to be labelled with black box warnings after sleepwalking deaths

May 2, 2019
Medical Communications, Research and Development FDA, ambien, black box warning, insomnia, sleeping pills, warning label

The FDA has said that Ambien, and other insomnia medications, must be labelled with a ‘black box warning’ – the …


Eisai and Purdue reveal positive Phase 3 data in insomnia

February 7, 2019
Research and Development Eisai, Purdue Pharma, insomnia, lemborexant, pharma

Partners Eisai and Purdue Pharma have lifted the curtain on Phase 3 clinical data on their jointly developed therapy lemborexant …

Merck image

Merck releases insomnia drug in US

February 4, 2015
Sales and Marketing FDA, Merck, belsomra, insomnia, orexin, suvorexant

Merck’s insomnia drug Belsomra is now available in the US to treat patients who have difficulty falling asleep or staying …

Merck image

FDA experts recommend Merck sleep pill

May 24, 2013
Research and Development, Sales and Marketing FDA, Merck, insomnia, suvorexant

Merck received welcome news this week from the FDA after one of the US regulator’s expert groups voted to approve …

Merck image

Merck releases new Phase III insomnia data

September 11, 2012
Research and Development, Sales and Marketing Merck, insomnia, suvorexant

Merck says it is on course to file its investigational insomnia drug suvorexant in the US by the end of …

Merck image

Merck’s sleep aid drug meets goals

June 15, 2012
Research and Development, Sales and Marketing FDA, Merck, insomnia, sleep disorder, suvorexant

Merck’s novel insomnia drug suvorexant has improved patients’ ability to fall asleep, according to new data from two Phase III …

Merck prepares insomnia candidate

February 7, 2012
Sales and Marketing Merck, insomnia

Merck is to file its new insomnia drug suvorexant, with US regulators later this year. Suvorexant is an orexin receptor …

GSK and Actelion drop insomnia treatment

January 30, 2011
Research and Development Actelion, GSK, insomnia

Actelion and GlaxoSmithKline are to abandon development of phase III insomnia drug almorexant because of problems with side-effects.Almorexant a dual …

GSK signs $1.5 billion insomnia collaboration

July 16, 2008
Sales and Marketing Actelion, GSK, insomnia

 GlaxoSmithKline has joined forces with Swiss biopharmaceutical company Actelion to bring a new insomnia treatment to market.The deal could be …

Latest content